Life Science Nation Newsletter  |  June 9, 2016  |  Issue 166

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (June 2 - June 8)
Invests in Preclinical and Phase I Oncology and Dermatology Drugs
Seeks Small Molecules and Biologics from North America and Europe
Seeks Huge Markets in Medtech and Diagnostics
Raises New Fund For Early Stage Biotech and Medtech Deals
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI @ TMCx Investors Panel

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

For the first time ever, RESI is taking the Innovation Challenge to MaRS Discovery District in Toronto, Canada on June 23. The competition will feature 30 handpicked early stage innovators from MaRS and across North America.

From a competitive pool of applicants, these entrepreneurs have been selected by LSN's scientific validation team based on their scientific merit and "investor readiness." The 30 companies bring together cutting-edge innovations across healthcare IT, biotech, medical device, and diagnostics...

By Cole Bunn, Senior Research Analyst, LSN

As we approach our third RESI event of 2016, LSN prides itself on continuing to foster an environment that allows entrepreneurs to effectively engage with investors, strategic partners and other key stakeholders that have the ability to move the needle in their venture. The value in robust networking/partnering coupled with first-hand insight from veteran investors and industry leaders, for diagnostic entrepreneurs is clear.

Moderated by Tom Miller, Managing Partner, GreyBird Ventures, this session will feature:
  • Nicola Urbani, Investment Director, Emerillon Capital
  • John Steuart, Managing Director, Steuart Ventures
  • Kathryn Deuchars, Director, Ontario Personalized Medicine Network, Ontario Genomics
  • Jeff Summer, SVP Business Development, Clinical Affairs & Genetics, LifeLabs
By Nono Hu, Director of Marketing, LSN

With the third installment of the summer reading series we take a look at the important decision of whether or not one should use a fundraising partner to help them in securing capital. Chapter 3 of The Life Science Executive's Fundraising Manifesto, "Going It Alone or Choosing a Fundraising Partner," tackles this question head-on, describing what companies would be a suitable fit for fundraising partners, providing a breakdown of the different types in the marketplace today, and advising readers on how to go about vetting a potential partner.

We hope you enjoy this chapter. Next week, join us for "Chapter 4: Categories of Life Science Investors." 


Life Science Nation | 9B Hamilton Place | Boston | MA | 02108